Latest News-Ascletis Pharma Inc. Mediaroom_Page

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science

HANGZHOU and SHAOXING, China, July 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascl...

2023-07-25 08:10 3197

Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

-- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023 SH...

2023-07-20 08:10 3517

Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascl...

2023-06-26 08:10 4150

Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there ...

2023-05-08 16:50 3808

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asclet...

2023-05-02 17:30 4923

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascl...

2023-02-27 17:15 4274

Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023

--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is co...

2023-02-21 08:10 3661

Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascle...

2023-02-16 17:10 3997

Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there...

2023-01-31 17:40 4108

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

--Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent ...

2023-01-26 21:08 4197

Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere

HANGZHOU and SHAOXING, China, Jan. 17, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascl...

2023-01-17 08:29 3669

Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

--The multiple-dose escalation Phase I clinical trial is expected to enroll 72 healthy subjects, an...

2023-01-16 08:10 4165

Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints

HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...

2023-01-02 19:24 4076

Latest News